Sidoti Csr Expects Weaker Earnings for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at Sidoti Csr decreased their Q3 2026 earnings per share (EPS) estimates for shares of USANA Health Sciences in a report issued on Wednesday, February 11th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings of $0.49 per share for the quarter, down from their previous estimate of $0.54. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.52 EPS, FY2026 earnings at $1.84 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at $0.65 EPS and FY2027 earnings at $2.77 EPS.

A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Zacks Research downgraded USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 7th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $36.00.

USANA Health Sciences Stock Down 0.0%

USNA stock opened at $20.95 on Monday. The firm has a 50 day moving average of $20.71 and a two-hundred day moving average of $23.69. USANA Health Sciences has a 12 month low of $18.48 and a 12 month high of $38.32. The company has a market capitalization of $382.97 million, a price-to-earnings ratio of 23.81, a P/E/G ratio of 0.95 and a beta of 0.67.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Pzena Investment Management LLC grew its stake in shares of USANA Health Sciences by 1.2% in the third quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock worth $33,407,000 after acquiring an additional 14,328 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in USANA Health Sciences by 1.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after purchasing an additional 21,793 shares during the period. Vanguard Group Inc. grew its position in USANA Health Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after purchasing an additional 57,249 shares during the last quarter. Dimensional Fund Advisors LP grew its position in USANA Health Sciences by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after purchasing an additional 17,318 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of USANA Health Sciences during the 4th quarter worth about $11,485,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.